{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T13:51:25Z","timestamp":1745934685355},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,22]]},"DOI":"10.7759\/cureus.36535","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T19:49:30Z","timestamp":1679514570000},"source":"Crossref","is-referenced-by-count":1,"title":["Acute Encephalopathy Due to Polypharmacy Interactions With the Use of Paxlovid: A Case Report"],"prefix":"10.7759","author":[{"given":"Samira","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Fama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Coronavirus (COVID-19) Update. FDA Authorizes Pharmacists to Prescribe Paxlovid with Certain Limitations | FDA. (2022). Accessed: December 22, 2021: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-pharmacists-prescribe-...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o1037","article-title":"Covid-19: what is the evidence for the antiviral Paxlovid?","volume":"377","author":"Extance A","year":"2022","unstructured":"Extance A. Covid-19: what is the evidence for the antiviral Paxlovid?. BMJ. 2022, 377:o1037. 10.1136\/bmj.o1037","journal-title":"BMJ"},{"key":"ref3","unstructured":"Ritonavir-Boosted Nirmatrelvir (Paxlovid) | COVID-19 Treatment Guidelines . (2022). Accessed. May 5, 2022: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antivirals-including-antibody-products\/ritonavir-boosted-nir...."},{"key":"ref4","unstructured":"Paxlovid Drug-Drug Interactions | COVID-19 Treatment Guidelines . (2022). Accessed. December 22, 2022: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antivirals-including-antibody-products\/ritonavir-boosted-nir...."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.15442","article-title":"Paxlovid drug interaction screening checklist updated","volume":"328","author":"Larkin HD","year":"2022","unstructured":"Larkin HD. Paxlovid drug interaction screening checklist updated. JAMA. 2022, 328:1290. 10.1001\/jama.2022.15442","journal-title":"JAMA"},{"key":"ref6","unstructured":"Fact sheet for healthcare providers. emergency use authorization for Paxlovid. (2022). Accessed: December 24, 2022: https:\/\/www.fda.gov\/media\/155050\/download."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/124825-acute-encephalopathy-due-to-polypharmacy-interactions-with-the-use-of-paxlovid-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:57:50Z","timestamp":1707508670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/124825-acute-encephalopathy-due-to-polypharmacy-interactions-with-the-use-of-paxlovid-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.36535","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,22]]}}}